← Back

Wire · opportunities

Regeneron Gained FDA Approval for RNAi Treatment Livsayis

Published

21 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at labroots.com →

◆ Verified

Fusion42 · 22 November 2026 · Fusion42 review

Regeneron received FDA approval for Livsayis, an RNA interference therapy for generalized myasthenia gravis, marking the first approved treatment for this chronic autoimmune neuromuscular disorder with a quarterly dosing schedule that offers a competitive advantage.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a new approval path to challenge chronic autoimmune diseases with less frequent dosing while beating weekly competitors. RNAi therapies like Livsayis now set a fresh benchmark for biotech drug regimens.

◆ Coverage

1 source · 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechrna-interferencedrug-approvalautoimmune-disordermyasthenia-gravischronic-diseasepharma-competitive